Sign Out
No formal drug-drug interaction studies have been conducted with XGEVA.
In clinical trials, XGEVA has been administered in combination with standard anti-cancer treatment and in subjects previously receiving bisphosphonates. The pharmacokinetics and pharmacodynamics of denosumab were not altered, by concomitant chemotherapy and/or hormone therapy nor by previous intravenous bisphosphonate exposure.
Continue with Google